GeoVax Labs (GOVX) Expected to Post Earnings on Monday

GeoVax Labs (NASDAQ:GOVX) will likely be posting its Q2 2026 results after the market closes on Monday, July 27th. Analysts expect GeoVax Labs to announce earnings of ($2.16) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, July 27, 2026 at 4:30 PM ET.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($2.62) EPS for the quarter, beating the consensus estimate of ($3.84) by $1.22. On average, analysts expect GeoVax Labs to post $-9 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

GeoVax Labs Trading Down 13.0%

Shares of NASDAQ:GOVX opened at $0.73 on Friday. The company has a market capitalization of $2.54 million, a price-to-earnings ratio of -0.04 and a beta of 3.68. GeoVax Labs has a 12-month low of $0.69 and a 12-month high of $20.64. The business has a 50-day moving average price of $1.55 and a 200 day moving average price of $1.84.

Wall Street Analyst Weigh In

Several research analysts have weighed in on GOVX shares. Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. D. Boral Capital restated a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a research report on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, GeoVax Labs presently has an average rating of “Reduce” and an average target price of $150.00.

Hedge Funds Weigh In On GeoVax Labs

Several hedge funds have recently bought and sold shares of GOVX. Jane Street Group LLC acquired a new position in GeoVax Labs in the 1st quarter valued at about $27,000. HRT Financial LP acquired a new stake in shares of GeoVax Labs during the fourth quarter worth about $31,000. Armistice Capital LLC acquired a new stake in shares of GeoVax Labs during the third quarter worth about $253,000. Finally, Renaissance Technologies LLC purchased a new position in shares of GeoVax Labs in the fourth quarter valued at approximately $104,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.